Chelsie Derman

A study found a strong link between headache disorders and suicide risk, including tension-type headaches.

A new study found antidepressant use drops by nearly 50% during pregnancy, but without increased psychotherapy, raising concerns about untreated depression risks.

Investigators in Korea developed and validated PSED-FA, a reliable tool to assess parental confidence in managing children's food allergies and nutrition.

ADP101 raised food allergy thresholds in children but missed its primary endpoint. Findings support further research into multi-food oral immunotherapy.

New ACP migraine guidelines recommend β-blockers, valproate, venlafaxine, or amitriptyline for episodic migraine prevention before using CGRP-targeting drugs.

January 2025 allergy research highlights dupilumab for CRSwNP, probiotics for food allergies, and links between parental age, environmental factors, and allergy risks.

This Month in Review highlights the top psychiatry news in January.

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

A study found propranolol significantly lowers ischemic stroke risk in women with migraine, highlighting its potential for stroke prevention in high-risk groups.

HCPLive spoke with Sachs about his study on palliative care for dementia, which reduced ED visits but didn’t significantly improve neuropsychiatric symptoms.

GH Research's phase 2b trial found GH001, an inhalable 5-MeO-DMT treatment, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

A study indicated that telomere length may not directly cause age-related brain diseases, but healthier lifestyles could counteract the harmful effects of shorter telomeres.

This month in review spotlights HCPLive’s coverage of gastroenterology pipeline news, a feature about gastroparesis and migraine, and recent GI research.

Axsome Therapeutics announced that the FDA approved the NDA for AXS-07 to treat acute migraine with or without aura on January 30, 2025.

A study showed that greater total cholesterol and low-density lipoprotein cholesterol were associated with a quicker decline in global cognition.

A study found palliative care for dementia did not improve neuropsychiatric symptoms but reduced emergency visits and hospitalizations over 2 years.

A trial found system- and community-based dementia care had no advantage over usual care, except for improved caregiver self-efficacy at 6 months.

Gastroparesis during migraine attacks can hinder oral medication absorption. Migraine experts discuss the connection between gastroparesis and migraine.

A study found penicillin allergy prevalence is higher in high-income countries (9.9%) than in middle-income ones (4.4%), highlighting disparities in reporting and research.

A new study found stimulant use in children dropped 19% early in the pandemic but rebounded, with the 2022 Adderall shortage prompting shifts to alternatives.

A study found no negative effect of food allergies on school performance, with better grades in severe cases, but results were nonsignificant in sibling analyses.

The FDA approved updated labeling for viloxazine ER capsules as an ADHD treatment, adding lactation data and details on serotonin 5-HT2C receptor activity.

Women experience more severe early PTSD symptoms than men, with re-experiencing and avoidance clusters being strongest. Men showed stronger anxious arousal patterns.

A new study showed that experiencing worsened allergic rhinitis symptoms in air-conditioned environments may predict disease severity.

A study found depressive symptoms in older individuals with normal cognition were linked to amyloid pathology in APOE ε4 noncarriers but not carriers.

A new study showed sedative, hypnotic, and anxiolytic use disorder diagnoses rose 3- to 5-fold from 2001–2019 among adolescents and young adults.

A new study identified psychiatric, neurological, and somatic comorbidities of intermittent explosive disorder.

HCPLive spoke with Mattingly about esketamine’s recent FDA approval as a monotherapy for treatment-resistant depression which works within hours or 1 – 2 days.

Dupilumab improves severe CRSwNP symptoms, such as nasal obstruction and quality of life, showing significant efficacy within 6-12 months.

Mindfulness eased opioid cravings in OUD patients on buprenorphine but showed no added benefit over recovery support for abstinence, substance use, or anxiety.